AMPX

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · derivative · entry 7

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,859,042

Underlying: Common stock · 24,809 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.12 to $3.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000006 · wk-form4_1699571059.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 24,809

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · derivative · entry 9

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,883,851

Underlying: Common stock · 22,969 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · nonDerivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F4 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.71 to $4.13, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · nonDerivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · derivative · entry 8

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,906,820

Underlying: Common stock · 56,702 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.06 to $4.35, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · derivative · entry 7

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,963,522

Underlying: Common stock · 70,329 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.21 to $4.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000004 · wk-form4_1697151321.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 70,329

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000002 · wf-form4_169532904095825.xml · derivative · entry 6

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,033,851

Underlying: Common stock · 6,484 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000002 · wf-form4_169532904095825.xml · nonDerivative · entry 4

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F3 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.11 to $4.32, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000002 · wf-form4_169532904095825.xml · nonDerivative · entry 3

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,484

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000002 · wf-form4_169532904095825.xml · derivative · entry 5

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,040,335

Underlying: Common stock · 143,516 shares

Expires 2027-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001942459-23-000002 · wf-form4_169532904095825.xml · nonDerivative · entry 2

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $4.18 to $4.76, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001942459-23-000002 · wf-form4_169532904095825.xml · nonDerivative · entry 1

Bornstein Jonathan · CIK 0001942459 · President of Amprius Lab

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 143,516

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The exercises and sales reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2023.

SEC source: 0001940928-23-000011 · wf-form4_169507320058205.xml · nonDerivative · entry 2

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,791

F2 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.85 to $3.96, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001940928-23-000011 · wf-form4_169507320058205.xml · nonDerivative · entry 1

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,421

F1 · price: The price reported in Column 4 is an average execution price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.70, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001940928-23-000008 · wf-form4_169455140238278.xml · derivative · entry 2

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 435,962

Underlying: Common stock · 80,000 shares

Expires 2024-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001940928-23-000008 · wf-form4_169455140238278.xml · nonDerivative · entry 1

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,791

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-23-022550 · wf-form4_168695345353776.xml · nonDerivative · entry 2

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,497,142

F3 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $8.603 to $9.418, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-022234 · wf-form4_168686034388341.xml · nonDerivative · entry 1

Gustanski Mary · CIK 0001725164 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 31,813

F1 · shares: The securities are represented by restricted stock units Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest in three equal annual installments on June 14, 2024, June 14, 2025 and June 14, 2026, subject to the reporting person's continued service on each applicable vesting date.

F2 · balance_after: Includes 31,813 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001628280-23-022550 · wf-form4_168695345353776.xml · nonDerivative · entry 1

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 2,558,142

F1 · price: The price reported in Column 4 is a cumulative average price. These shares were sold in multiple transactions at prices ranging from $9.28 to $9.88, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

F2 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the reporting person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001628280-23-021897 · wf-form4_168660901546217.xml · nonDerivative · entry 1

DIXON DONALD R · CIK 0001045434 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,895

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date.

F2 · balance_after: Includes 17,895 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001628280-23-021893 · wf-form4_168660888831135.xml · nonDerivative · entry 1

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,895

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date.

F2 · balance_after: Includes 17,895 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001628280-23-021895 · wf-form4_168660895645462.xml · nonDerivative · entry 1

Chu Steven · CIK 0001296381 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,395

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date.

F2 · balance_after: Includes 17,895 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001628280-23-021899 · wf-form4_168660908751914.xml · nonDerivative · entry 1

BAYLESS KATHLEEN A · CIK 0001230569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 36,253

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date.

F2 · balance_after: Includes 36,253 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001628280-23-021891 · wf-form4_168660880489496.xml · nonDerivative · entry 1

HSIEH Wen Hsuan · CIK 0001835160 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,895

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents the reporting person's right to receive one share of issuer's common stock. 100% of the restricted stock units vest on the earlier of (i) the one-year anniversary of the date the restricted stock units were granted and (ii) the day before the next annual meeting of stockholders, subject to the reporting person's continued service as of the vesting date.

F2 · balance_after: Includes 17,895 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001628280-23-013618 · wf-form4_168262799381248.xml · nonDerivative · entry 1

BAYLESS KATHLEEN A · CIK 0001230569 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,762

F1 · shares: The securities are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest in three equal annual installments on April 25, 2024, April 25, 2025 and April 25, 2026, subject to the reporting person's continued service on each applicable vesting date.

F2 · balance_after: Includes 34,762 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.

SEC source: 0001940928-22-000002 · wf-form4_167114761444644.xml · derivative · entry 2

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 515,962

Underlying: Common stock · 30,000 shares

Expires 2024-03-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001940928-22-000002 · wf-form4_167114761444644.xml · nonDerivative · entry 1

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001940928-23-000002 · wf-form4_168314942961241.xml · nonDerivative · entry 1

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,791

F1 · shares: The reporting person received 29,791 shares of common stock on net exercise of option to purchase 30,000 shares of common stock. The issuer withheld 209 shares of common stock underlying the option for payment of the exercise price, using the closing stock price on December 14, 2022, pursuant to the terms of the issuer's 2022 Equity Incentive Plan.

SEC source: 0000899243-22-031387 · doc4.xml · derivative · entry 7

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,535,000 shares

Expires 2027-09-14

F2 · kind: The securities were distributed in-kind, pro-rata and for no additional consideration to the members of Kensington Capital Sponsor IV LLC in connection with its liquidating distribution. As a result of the transaction reported herein, the Reporting Person is no longer a 10% holder of the issuer.

F4 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable upon exercise thereof has been declared effective (or, in the case of all of the warrants in Table II, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

SEC source: 0000899243-22-031387 · doc4.xml · derivative · entry 6

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000,000 shares

Expires 2027-09-14

F2 · kind: The securities were distributed in-kind, pro-rata and for no additional consideration to the members of Kensington Capital Sponsor IV LLC in connection with its liquidating distribution. As a result of the transaction reported herein, the Reporting Person is no longer a 10% holder of the issuer.

F4 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable upon exercise thereof has been declared effective (or, in the case of all of the warrants in Table II, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

SEC source: 0000899243-22-031387 · doc4.xml · derivative · entry 5

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,535,000

Underlying: Common Stock · 6,535,000 shares

Expires 2027-09-14

F3 · kind: The Reporting Person acquired these securities in connection with the initial public offering of Kensington Capital Acquisition Corp. IV, which is the Issuer and changed its name to Amprius Technologies, Inc. upon closing of a business combination transaction and is reporting the ownership thereof in connection with such closing. These securities were previously not beneficially owned for purposes of reporting their ownership on this Form.

F4 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable upon exercise thereof has been declared effective (or, in the case of all of the warrants in Table II, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

SEC source: 0000899243-22-031387 · doc4.xml · derivative · entry 4

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000,000

Underlying: Common Stock · 16,000,000 shares

Expires 2027-09-14

F3 · kind: The Reporting Person acquired these securities in connection with the initial public offering of Kensington Capital Acquisition Corp. IV, which is the Issuer and changed its name to Amprius Technologies, Inc. upon closing of a business combination transaction and is reporting the ownership thereof in connection with such closing. These securities were previously not beneficially owned for purposes of reporting their ownership on this Form.

F4 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable upon exercise thereof has been declared effective (or, in the case of all of the warrants in Table II, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

SEC source: 0000899243-22-031387 · doc4.xml · derivative · entry 3

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,857,142 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Upon completion of the Issuer's business combination transaction, the Issuer's Class B Ordinary Shares converted into shares of Common Stock of the Issuer. At the time the Class B shares were issued, the Issuer was a Cayman Islands exempted company incorporated with limited liability named "Kensington Capital Acquisition Corp. IV." In connection with a business combination transaction, the Issuer became a Delaware corporation and changed its name to "Amprius Technologies, Inc."

F1 · derivative.exercise_date: Upon completion of the Issuer's business combination transaction, the Issuer's Class B Ordinary Shares converted into shares of Common Stock of the Issuer. At the time the Class B shares were issued, the Issuer was a Cayman Islands exempted company incorporated with limited liability named "Kensington Capital Acquisition Corp. IV." In connection with a business combination transaction, the Issuer became a Delaware corporation and changed its name to "Amprius Technologies, Inc."

F1 · derivative.expiration_date: Upon completion of the Issuer's business combination transaction, the Issuer's Class B Ordinary Shares converted into shares of Common Stock of the Issuer. At the time the Class B shares were issued, the Issuer was a Cayman Islands exempted company incorporated with limited liability named "Kensington Capital Acquisition Corp. IV." In connection with a business combination transaction, the Issuer became a Delaware corporation and changed its name to "Amprius Technologies, Inc."

SEC source: 0000899243-22-031387 · doc4.xml · nonDerivative · entry 2

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F2 · shares: The securities were distributed in-kind, pro-rata and for no additional consideration to the members of Kensington Capital Sponsor IV LLC in connection with its liquidating distribution. As a result of the transaction reported herein, the Reporting Person is no longer a 10% holder of the issuer.

SEC source: 0000899243-22-031387 · doc4.xml · nonDerivative · entry 1

Kensington Capital Sponsor IV LLC · CIK 0001908586 · Former 10% holder (see ftn 2)

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,124,642

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Upon completion of the Issuer's business combination transaction, the Issuer's Class B Ordinary Shares converted into shares of Common Stock of the Issuer. At the time the Class B shares were issued, the Issuer was a Cayman Islands exempted company incorporated with limited liability named "Kensington Capital Acquisition Corp. IV." In connection with a business combination transaction, the Issuer became a Delaware corporation and changed its name to "Amprius Technologies, Inc."

SEC source: 0000899243-22-031396 · doc4.xml · derivative · entry 4

DIXON DONALD R · CIK 0001045434 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 270,251

Underlying: Common Stock · 270,251 shares

Expires 2032-04-13

F6 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio.

F5 · derivative.exercise_date: 1/48 of the total number of shares issuable upon exercise of the option vested on February 1, 2022, and 1/48 of the total number of shares issuable upon exercise of the option vest monthly thereafter until fully vested on January 1, 2026.

SEC source: 0000899243-22-031400 · doc4.xml · derivative · entry 5

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 218,385

Underlying: Common Stock · 218,385 shares

Expires 2032-04-13

F1 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio.

F3 · derivative.exercise_date: 1/48 of the total number of shares issuable upon exercise of the option vested on February 1, 2023, and 1/48 of the total number of shares issuable upon exercise of the option vest monthly thereafter until fully vested on January 1, 2027.

SEC source: 0000899243-22-031400 · doc4.xml · derivative · entry 4

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,795

Underlying: Common Stock · 72,795 shares

Expires 2031-06-16

F1 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio.

F2 · derivative.exercise_date: 1/48 of the total number of shares issuable upon exercise of the option vested on July 17, 2021, and 1/48 of the total number of shares issuable upon exercise of the option vest monthly thereafter until fully vested on June 17, 2025.

SEC source: 0000899243-22-031400 · doc4.xml · derivative · entry 3

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,795

Underlying: Common Stock · 72,795 shares

Expires 2028-03-19

F1 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio.

SEC source: 0000899243-22-031400 · doc4.xml · derivative · entry 2

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 181,987

Underlying: Common Stock · 181,987 shares

Expires 2027-07-11

F1 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio.

SEC source: 0000899243-22-031400 · doc4.xml · derivative · entry 1

Stefan Constantin Ionel · CIK 0001940928 · Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 545,962

Underlying: Common Stock · 545,962 shares

Expires 2024-03-15

F1 · price: On September 14, 2022, the Issuer completed a business combination (the "Business Combination") pursuant to the Business Combination Agreement, by and among the Issuer, a wholly owned subsidiary of the Issuer, and Amprius Technologies Operating, Inc. ("Legacy Amprius") At the effective time of the Business Combination (the "Effective Time"), each Legacy Amprius option was converted into an option to purchase a number of shares of Common Stock of the Issuer equal to the product (rounded down to the nearest whole number) of (i) the number of shares of Legacy Amprius common stock subject to the Legacy Amprius option immediately prior to the Effective Time multiplied by (ii) an exchange ratio of approximately 1.45590, at an exercise price per share (rounded up to the nearest whole cent) equal to (A) the exercise price per share of such Legacy Amprius option immediately prior to the Effective Time divided by (B) the Exchange Ratio.

SEC source: 0000899243-22-031386 · doc4.xml · derivative · entry 10

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2027-09-14

F10 · price: The securities were issued by the Issuer at the closing of the foregoing business combination transaction upon conversion of a "working capital" loan made to the Issuer.

F9 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable on exercise thereof has been declared effective (or, in the case of all of the warrants in Table II except for the warrants with an exercise price of $12.50, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

SEC source: 0000899243-22-031386 · doc4.xml · derivative · entry 9

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 111,000

Underlying: Common Stock · 111,000 shares

Expires 2027-09-14

F5 · kind: Acquired in a PIPE transaction that closed concurrently with the closing of the Issuer's business combination transaction on September 14, 2022. In the PIPE transaction, the Reporting Person acquired 111,000 shares of Common Stock and 111,000 PIPE Warrants (described in Table II) for an aggregate purchase price of $1,110,000.

F5 · price: Acquired in a PIPE transaction that closed concurrently with the closing of the Issuer's business combination transaction on September 14, 2022. In the PIPE transaction, the Reporting Person acquired 111,000 shares of Common Stock and 111,000 PIPE Warrants (described in Table II) for an aggregate purchase price of $1,110,000.

F9 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable on exercise thereof has been declared effective (or, in the case of all of the warrants in Table II except for the warrants with an exercise price of $12.50, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

F4 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the Reporting Person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0000899243-22-031386 · doc4.xml · derivative · entry 8

MIRRO JUSTIN E · CIK 0001641982 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 4,700,000

Underlying: Common Stock · 4,700,000 shares

Expires 2027-09-14

F3 · kind: The securities were distributed in-kind, pro-rata and for no additional consideration to the members of the Sponsor in connection with its liquidating distribution.

F8 · kind: The Sponsor acquired these securities in connection with the initial public offering of Kensington Capital Acquisition Corp. IV, which (as discussed above) is the Issuer and changed its name to Amprius Technologies, Inc. upon closing of the foregoing business combination transaction and is reporting the ownership thereof in connection with such closing. These securities were previously not beneficially owned for purposes of reporting their ownership on this Form.

F3 · price: The securities were distributed in-kind, pro-rata and for no additional consideration to the members of the Sponsor in connection with its liquidating distribution.

F9 · derivative.exercise_date: The securities become exercisable on October 14, 2022, provided that in no event are the securities exercisable unless a registration statement registering the shares issuable on exercise thereof has been declared effective (or, in the case of all of the warrants in Table II except for the warrants with an exercise price of $12.50, until the 61st business day following the closing of the foregoing business combination if such a registration statement has not previously been declared effective).

F4 · ownership.nature: The securities are owned by Kensington Capital Partners, LLC, of which the Reporting Person is the managing member. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.